This figure illustrates the effects of GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors on composite cardiovascular outcomes, including all-cause mortality, progression to systolic heart failure, acute myocardial infarction, and stroke, after propensity score matching
Real-world evidence suggests favorable cardiovascular effects, with some retrospective analyses showing tirzepatide may reduce major cardiovascular events by approximately 14% compared to semaglutide
Lipophilic compounds can become trapped in the mucus rather than diffusing through to the epithelium, reducing absorption efficiency
For overweight patients, the risk was greater than 7.6 times higher compared with other medications
State-licensed 503A pharmacies can compound semaglutide for patient-specific prescriptions with documented clinical justification, such as an inactive-ingredient allergy or a dose not commercially available
Protein is digested more slowly than carbohydrates, helping to delay stomach emptying and promote lasting fullness
